Finding the biomarkers of response to anti-VEGF treatment is today a priority of the research, according to Marc De Smet, MD, PhD. Response is widely variable, and biomarkers will help tailoring treatment options to the needs of individual patients.
Home / Perspective: Marc De Smet, MD, PhD
Perspective: Marc De Smet, MD, PhD
Other Perspective
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
High-dose Aflibercept: the PHOTON and PULSAR trials
Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and th
What is the current situation of ophthalmology in Ukraine?
Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.